Stock CGEM CULLINAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
25.3 USD +31.43% Intraday chart for Cullinan Therapeutics, Inc. +61.56% +148.28%
Apr. 16 Transcript : Cullinan Oncology, Inc. - Special Call
Apr. 16 Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 674.1 482.9 435.9 1,090 - -
Enterprise Value (EV) 1 383.6 15.61 -31.13 656.2 662.9 1,090
P/E ratio -10.2 x 4.43 x -2.76 x -7.42 x -8.25 x -8.13 x
Yield - - - - - -
Capitalization / Revenue 35.6 x - - 603 x 82.4 x 46.3 x
EV / Revenue 20.2 x - - 363 x 50.1 x 46.3 x
EV / EBITDA -5.65 x 0.11 x 0.16 x -3.82 x -4.09 x -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 1.61 x 0.92 x 0.96 x 2.77 x 3.21 x -
Nbr of stocks (in thousands) 43,685 45,772 42,781 43,066 - -
Reference price 2 15.43 10.55 10.19 25.30 25.30 25.30
Announcement Date 3/17/22 3/9/23 3/14/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 18.94 - - 1.806 13.23 23.52
EBITDA 1 - -60.27 -67.9 144.7 -190.3 -172 -162.2 -
EBIT 1 -22.27 -60.34 -67.95 144.6 -190.6 -190.3 -199.7 -216.5
Operating Margin - - -358.73% - - -10,534.81% -1,509.85% -920.73%
Earnings before Tax (EBT) 1 - -59.46 - 151.3 -169.2 -172.2 -184.7 -203.2
Net income 1 - -51.8 -65.57 111.2 -153.2 -171.1 -178.1 -195.3
Net margin - - -346.14% - - -9,474.74% -1,346.63% -830.31%
EPS 2 -1,127 -3.637 -1.520 2.380 -3.690 -3.412 -3.068 -3.112
Free Cash Flow - -29.78 - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 11/2/20 3/30/21 3/17/22 3/9/23 3/14/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -11.5 -34.35 -32.66 239.7 -29.77 -32.61 -62.76 -37.6 -45.24 -45.48 -46.73 -47.62 -48.72 -50.22 -
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -11.31 - - 240.1 -27.41 -28.95 -58.14 -32.21 -39.18 -39.68 -43.25 -44.16 -44.56 -45.75 -
Net income 1 -9.858 -32.51 -12.1 174.9 -24.8 -26.78 -57.96 -32.21 -39.18 -23.8 -42.7 -43.12 -43.83 -45.63 -
Net margin - - - - - - - - - - - - - - -
EPS 2 -0.5000 -0.7400 -0.2700 3.770 -0.5400 -0.5900 -1.420 -0.8200 -0.9100 -0.5400 -0.8920 -0.8650 -0.8450 -0.7883 -0.7700
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/9/21 3/17/22 5/16/22 8/10/22 11/14/22 3/9/23 5/11/23 8/10/23 11/8/23 3/14/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 210 290 467 467 433 427 -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow -29.8 - - - - - -
ROE (net income / shareholders' equity) - -16.1% 23.2% -31% -34.4% -34.2% -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 -0.9200 9.590 11.50 10.60 9.150 7.880 -
Cash Flow per Share - - - - - - -
Capex 1 0.01 - 1.13 0.21 0.22 0.23 -
Capex / Sales - - - - 12.07% 1.73% -
Announcement Date 3/30/21 3/17/22 3/9/23 3/14/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
25.3 USD
Average target price
28.71 USD
Spread / Average Target
+13.50%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CULLINAN THERAPEUTICS, INC. Stock Cullinan Therapeutics, Inc.
+148.28% 1.09B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CGEM Stock
  4. Financials Cullinan Therapeutics, Inc.